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ABSTRACT
Functional telomeres are required to maintain
the replicative ability of cancer cells and represent
putative targets for G-quadruplex (G4) ligands. Here,
we show that the pentacyclic acridinium salt
RHPS4, one of the most effective and selective G4
ligands, triggers damages in cells traversing S
phase by interfering with telomere replication.
Indeed, we found that RHPS4 markedly reduced
BrdU incorporation at telomeres and altered the
dynamic association of the telomeric proteins
TRF1, TRF2 and POT1, leading to chromosome
aberrations such as telomere fusions and telomere
doublets. Analysis of the molecular damage
pathway revealed that RHPS4 induced an ATR-
dependent ATM signaling that plays a functional
role in the cellular response to RHPS4 treatment.
We propose that RHPS4, by stabilizing G4 DNA at
telomeres, impairs fork progression and/or telo-
mere processing resulting in telomere dysfunction
and activation of a replication stress response path-
way. The detailed understanding of the molecular
mode of action of this class of compounds makes
them attractive tools to understand telomere biol-
ogy and provides the basis for a rational use of G4
ligands for the therapy of cancer.
INTRODUCTION
Telomeres are the structures at the end of eukaryotic
linear chromosomes. Human telomeres consist of
tandem repeats of the hexanucleotide sequence TTAGG
G in double strand, except for a terminal 30 G-rich over-
hang (1,2). Mammalian telomeres are associated with shel-
terin, a protein complex that functions to protect DNA
ends from being recognized and repaired as double strand
breaks and from triggering DNA damage responses (3).
In addition, telomeres are transcribed, giving rise to chro-
matin-associated G-rich transcripts, named TERRA,
whose function is still elusive (4,5).
Telomeres can fold into t-loops that may result from
invasion of the 30-overhang into duplex DNA (6) or into
G-quadruplex (G4) DNA, an unusual DNA conformation
based on guanine quartets (7). These structures might be a
source of diﬃculty for the passage of the replication fork
and would need to be resolved to allow DNA replication
and telomerase elongation (8). Telomeres have evolved as
a puzzling diversity of mechanisms to accommodate the
replication problems and to reconstitute capped telomeres.
Telomere replication relies on a strong synergy among the
conventional replication machinery, telomere protection
systems, DNA damage response pathway and chromo-
somal organization (9). Moreover, experiments performed
both in yeast and mammalian cells in vitro indicate that
telomere-binding proteins could play an essential role in
coordinating telomere replication by preventing stalled
*To whom correspondence should be addressed. Tel: +39 06 52662569; Fax: +39 06 52662505; Email: biroccio@ifo.it
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
 2009 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.forks, which may result in telomere attrition or increased
recombination (10,11). Indeed, telomeric complex is
dynamic during cell cycle and the binding of telomeric
proteins to TTAGGG repeats changes as the cycle pro-
gresses (12). Recent studies suggest that replication fork
naturally pauses or stalls at the telomeres triggering a
transient ATM and Rad3-related (ATR)/ataxia-telangiec-
tasia mutated (ATM) DNA damage response, which is not
suﬃcient to stop cell proliferation but which is likely to be
required for a proper telomere processing (13). The tran-
sient DNA damage response is essential for telomere pro-
cessing and recruitment of modifying enzymes. Increasing
evidences indicate that RecQ-like helicases Werner’s syn-
drome protein (WRN), Bloom’s syndrome protein (BLM)
and other factors are capable of removing or remodeling
the telomeric structures that can impair fork progression.
WRN and BLM helicases are proposed to remove the
secondary structure, i.e. a G4 that can be formed in the
G-rich strand, while topoisomerase (TOPO) I can rapidly
relax the accumulation of positive supercoiling that
is transiently generated when replication approaches a
t-loop (8,14,15).
The burgeoning knowledge about the structure of
telomeres and the roles of various factors involved in tel-
omere maintenance provides several possible targets for
pharmacological intervention (16). To date, the area that
has received major drug discovery attention is the target
of the telomeric G4 structure. G4-interacting agents
are small molecules that are able to bind to, and stabilize,
the telomeric DNA in a quadruplex conformation,
thereby inhibiting telomere extension by telomerase (17).
Interestingly, TERRA molecules can fold into G4 struc-
tures, suggesting that this telomeric RNA could be a target
of G4 ligands (18). In fact, a wealth of data indicates
that G4-interacting compounds might disrupt telomere
architecture, both in telomerase- and alternative lengthen-
ing of telomeres (ALT)-positive tumors, causing immedi-
ate and profound eﬀects on cell proliferation (19). The
pentacyclic acridinium salt RHPS4 (3,11-diﬂuoro-6,8,13-
-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) is
one of the most eﬀective and selective G4 ligands (20).
Our group recently demonstrated that in addition to its
telomerase inhibitory properties, this drug exerts an antic-
ancer eﬀect by telomeric chromatin alteration (21). Here,
we report that stabilization of telomeric DNA quadruplex
by RHPS4 can interfere with telomere replication, trigger-
ing an ATR-dependent damage response pathway.
MATERIALS AND METHODS
Cells and culture conditions
BJ ﬁbroblasts expressing hTERT and SV40 early region
(BJ-HELT) were maintained as previously described (22).
The wild-type and ChK2-, p53- or p21-deﬁcient HCT116
cells were obtained by Dr Vogelstein, Johns Hopkins
University. The GM847/ATR-wt and GM847/ATR-ki
were a generous gift from Dr Rosselli, Institut Gustave
Roussy, Villejuif, France. The expression of ATR iso-
forms was induced by the addition of 1mg/ml of doxycy-
cline to the medium. All the lines were grown in Dulbecco
modiﬁed eagle medium (DMEM; Invitrogen, Carlsbad,
CA, USA) containing 10% fetal calf serum.
Transfection
For RNA interference experiments, cells were transfected
with 100nM of siATM or siATR or siBLM smart pool
(Dharmacon, Chicago, IL, USA) in a 35-mm Petri
dishes using Lipofectamine 2000 reagent (Lipofectamine
2000, Invitrogen). siGFP was used as negative control
(Dharmacon).
Antibodies
The following antibodies were used: mAb and pAb anti-
gH2AX (Upstate, Lake Placid, NY, USA); mAb anti-
PCNA and mAb anti-b-actin (Sigma Chemicals, Milano,
Italy); mAb anti-TRF2 (Imgenex, San Diego, CA, USA);
pAb anti-POT1, pAb anti-S1981 ATM, mAb anti-ATR,
pAb anti-BLM, pAb and mAb anti-TRF1 (for immuno-
ﬂuorescence application) (Abcam, Cambridge, UK); pAbs
anti-TRF1 (for ChIP application), anti-p21, mAb anti-p53
and pAb anti-ATRIP (Santa Cruz Biotechnology, Santa
Cruz, CA, USA); pAb anti-53BP1 (Novus Biologicals,
Littleton, CO, USA); mAb anti-BrdU (Becton
Dickinson, Heidelberg, Germany); pAb anti-Ser15 p53,
pAb anti-Chk1, pAb anti-Ser345 Chk1, pAb anti-Chk2
and pAb anti-Thr68 Chk2 (Cell Signaling); pAb anti-
WRN (Bethyl Laboratories, Montgomery, TX, USA);
mAb anti-ATM (a generous gift from Dr D. Delia,
Istituto Nazionale Tumori, Milano, Italy) and mAb
anti-HSP 72/73 (Calbiochem, Cambridge, MA, USA).
In vitro treatments
Treatments were performed 24h after plating and were
used at the following doses: 0.5mM RHPS4 for diﬀerent
time of exposure, 2mM hydroxyurea (HU; Sigma) for 3h,
ultraviolet (UV) 10J/m
2, ionizing radiation (IR) 5Gy. Cell
counts and viability (trypan blue dye exclusion) were
determined in each experiment. For synchronization,
BJ-HELT cells were grown to 50% conﬂuence in 10-cm
plates and incubated overnight with 0.5mM HU. The cells
were released by replacing the medium in presence or
absence of 0.5mM RHPS4.
Cell viability
Cell viability was evaluated by using the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
MTT assay (Sigma) according to manufacturer’s
instructions.
Western blotting
Western blot and detection were performed as previously
reported (23). To check the amount of proteins transferred
to nitrocellulose membrane, HSP 72/73 or b-actin was
used as control. The relative amounts of the transferred
proteins were quantiﬁed by scanning the autoradiographic
ﬁlms with a gel densitometer scanner (Bio-Rad, Milano,
Italy) and normalized to the related HSP 72/73 or b-actin
amounts.
5354 Nucleic Acids Research, 2009, Vol. 37,No. 16Immunofluorescence
Cells were ﬁxed in 2% formaldehyde and permeabilized
in 0.25% Triton X-100 in Phosphate buﬀered saline (PBS)
for 5min at room temperature. For immunolabeling
experiments, cells were incubated with primary antibody,
washed in PBS and incubated with the following second-
ary antibodies: TRITC conjugated Goat anti-Rabbit,
FITC conjugated Goat anti-Mouse (Jackson Lab).
Nuclei were visualized using DAPI or Hoechst (Sigma).
For metaphase chromosomes preparation, cells were trea-
ted with 0.1mg/ml demecolcine (Sigma) of for 4h and
harvested and washed in 75mM KCl for 5min at 378C.
After centrifugation, cells were ﬁxed in MetOH and acetic
acid in the ratio 3:1 overnight and then spread on slides.
Hybridization with Rodamine-coupled Peptide Nucleic
Acid (PNA) was performed as described by Lenain et al.
(24). Images of metaphases were captured with a 100 
objective. Fluorescence signals were recorded by using a
Leica DMIRE2 microscope equipped with a Leica DFC
350FX camera and elaborated by a Leica FW4000 decon-
volution software (Leica, Solms, Germany) or by confocal
analysis obtained with a Zeiss LSM 510 META Laser
Scanning Microscope (Zeiss, Oberkochen, Germany).
Chromatin immunoprecipitation (ChIP)
Cells were synchronized at the G1/S boundary as
described above. After releasing from the HU block,
cells were harvested every 2h by scraping and were ﬁxed
with 1% formaldehyde for 10min at room temperature.
Chromatin immunoprecipitation (ChIP) assay was
performed as previously described (21).
For chromatin BrdU incorporation, before harvesting
each time point, the cells were incubated with 20mM
BrdU (Sigma) for 1h. After dot blotting, BrdU incorpo-
ration into telomeric DNA was evaluated by western blot
analysis.
Flow cytometric analysis
Cell cycle analysis was performed by ﬂow cytometry
(Becton-Dickinson) as previously described (25). For the
separation of G0/G1 from S–G2/M cells, single-cell sus-
pension was incubated with Hoechst for staining DNA
and sorted using FACS Vantage DiVa (BD Biosciences,
San Jose, CA, USA). Cell cycle phases were sorted and
isolated using electronic gating based on ﬂuorescence
emission of Hoechst after excitation with UV laser emit-
ting 350–360nm UV light.
Progression of cells through the cell cycle phases was
analyzed by ﬂow cytometry using BrdU (Becton-
Dickinson) incorporation, as previously described (26).
Brieﬂy, at diﬀerent times of RHPS4 treatment, cells
were pulsed with BrdU at a ﬁnal concentration of 10mM
for 15min, and after the appropriate intervals in BrdU-
free medium (from 4 to 16h) the DNA was denatured.
Cells were then incubated with 2mg/ml of mouse anti-
BrdU (clone BMC 9318, Roche Diagnostics Corp.,
Indianapolis, IN, USA) for 30min at room tempera-
ture, and the BrdU-positive cells were revealed with
FITC-conjugated anti-mouse mAb (1:20, Dako, SA,
Glostrup, Denmark).
Statistical analysis
The experiments have been repeated from three to ﬁve
times and the results obtained are presented as means 
SD. Signiﬁcant changes were assessed by using Student’s
t-test for unpaired data, and P-values < 0.05 were con-
sidered signiﬁcant.
RESULTS
RHPS4 activates DNA damage response during
replication
Previously, we showed that exposure of transformed ﬁbro-
blasts (BJ-HELT cells) to the G4-interactive molecule
RHPS4 caused a rapid and speciﬁc DNA damage at the
telomeres with the formation of several telomeric foci con-
taining damage response factors like phosphorylated
H2AX (gH2AX) (21, Figure 1A). Of note, drug-induced
phosphorylation of H2AX was restricted to a fraction of
RHPS4-treated cells (Figure 1B), suggesting that, similar
to treatment with HU and low-UV dose, but in contrast to
IRs, RHPS4 can induce a replication-dependent DNA
damage. To verify this hypothesis and determine which
fraction of the cells formed gH2AX foci, we performed
co-immunostaining to gH2AX and the proliferating cell
nuclear antigen PCNA, which accumulates in the nucleus
during S phase. In the case of RHPS4, as well as of HU
and UV, gH2AX foci formation was restricted to PCNA-
positive cells, whereas in the case of IR, gH2AX foci
formed both in PCNA-positive and -negative cells
(Figure 1B and C).
The relationship between gH2AX foci formation and
DNA replication was also examined by using cell sorting.
For RHPS4, HU and UV, cells in the proliferative com-
partment (S–G2/M) had the highest gH2AX expression,
whereas gH2AX was lowest in the cells in the G0/G1 phase
of cell cycle (Figure 1D). In contrast, for IR, gH2AX
was equally distributed in all of the cell cycle phases
(Figure 1D).
To further conﬁrm that the phosphorylation of H2AX
upon RHPS4 treatment is related to replication, BJ-HELT
ﬁbroblasts were synchronized by treatment with sub-lethal
dose of HU, an agent that causes replication fork arrest
due to nucleotide depletion, blocking the cells at the G1/S
boundary. Synchronization with HU-induced phosphory-
lation of H2AX rapidly recovered by release in drug-free
medium (Figure 1E and F). Importantly, cells released
from the HU block in the presence of RHPS4 showed
phosphorylation of H2AX when analyzed during S and
G2/M phases (from 4 to 8h after HU removal) (Figure 1E
and F). These results, conﬁrmed by western blotting
(Figure 1G), demonstrate that a signiﬁcative phosphory-
lation of H2AX is a very early response to RHPS4 when
the cells enter into S phase.
As a consequence of the damage in S phase, cells chron-
ically exposed to RHPS4 showed a delay in the S–G2 tran-
sition at Day 4 of drug exposure and at Day 5 most of the
cells were arrested (Figure 2A and B). The very early
Nucleic Acids Research, 2009,Vol.37, No. 16 5355Figure 1. Replication-dependent induction of damage by RHPS4. (A) BJ-EHLT ﬁbroblasts treated with RHPS4 for 16h were ﬁxed and processed for
IF by using antibodies against gH2AX and TRF1. Representative deconvolution images are reported. (B) BJ-HELT ﬁbroblasts were exposed to the
following treatment: 0.5mM RHPS4 for 16h, 2mM HU for 3h, UV 10J/m
2, IR 5Gy. Representative images of IF against gH2AX and PCNA were
acquired with a Leica Deconvolution microscope (magniﬁcation:  40). (C) Percentage of gH2AX+/PCNA- or gH2AX+/PCNA+ nuclei in the
indicated samples. The mean of three independent experiments with comparable results is shown. (D) HeLa cells untreated or exposed to the
indicated treatment were sorted by FACS according to the DNA content. The fractions corresponding to cells in G0/G1 and S–G2/M cell cycle
phases were cytocentrifuged on cover slips and stained for IF against gH2AX. Histogram represents the percentage of gH2AX-positive cells under
diﬀerent stimulations. The mean of three independent experiments with comparable results is shown. (E) BJ-HELT ﬁbroblasts were treated with a
low dose of HU (0.5mM for 16h) to block cells at the G1–S boundary. Then, the medium was replaced to release cells and in the treated samples
0.5mM RHPS4 was added. Cells were ﬁxed at the indicated times for cell cycle analysis (upper panel) and IF against gH2AX. Representative images
of IF are reported in the lower panel (magniﬁcation:  63). Percentage of gH2AX-positive nuclei (F) and western blotting analysis of gH2AX (G)i n
control and RHPS4-treated samples at diﬀerent times after HU release.
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rimental eﬀects on cell cycle (Figure 2) suggest that cells
have to be chronically exposed to the drug to accumulate
enough damages. Indeed, while a short time of RHPS4
exposure is suﬃcient to phosphorylate H2AX but the
cells recover from the damage, long-term treatment cre-
ates chronic damages ultimately leading to cell death
(Supplementary Figure 1).
RHPS4 interferes with replication of the telomeres
Altogether, the facts that RHPS4 speciﬁcally triggers
telomere damage and the signaling of RHPS4-induced
damages occurs in S phase (Figure 1A) suggest that
RHPS4 can interfere with telomere replication. To address
this question, we used a combination of BrdU incorpora-
tion (to mark replicating DNA) with ChIP assay to
measure the amount of replicating DNA associated to
telomeric proteins (12). BJ-HELT ﬁbroblasts were
synchronized with HU, and released in drug-free or
RHPS4-containing medium. Prior to harvest of each indi-
vidual time point, the cells were incubated with BrdU for
1h. Cell cycle progression was analyzed by FACS, and
DNA content was used as reference for cell cycle phase
(Figure 3A). Analysis of untreated samples resulting from
immunoprecipitations with antibodies against telomeric-
repeat binding factor 1 (TRF1) and TRF2 demonstrated
that BrdU was incorporated during S and G2 phases of
cell cycle consistent with an early and late telomere repli-
cation or telomere processing (12, Figure 3B). The BrdU
incorporation pattern was accompanied by transient dis-
sociation of the telomeric proteins: TRF1 showed a
decrease at the telomeres in S and G2 phases, while
TRF2 and protection of telomeres 1 (POT1) exhibited a
dip only during G2 followed a rapid recovery of binding
(10, Figures 3D–E). Treatment with RHPS4 did not
modify cell cycle progression at the indicated time points
(Figure 3A) and cells incorporated BrdU to the same
extent of untreated ones (Figure 3B, input lines, and C,
left panel). However, RHPS4 markedly decreased the
amount of BrdU in the chromatin fragments of immuno-
precipitated with TRF1 or TRF2 antibodies (Figure 3B
and C). Moreover, the pattern of the three telomeric pro-
teins was remarkably diﬀerent in RHPS4-treated samples
(Figure 3D and E). Indeed, compared with untreated ones
there is less telomere-bound TRF1 in RHPS4-treated cells
progressing through S and G2 (Figure 3D and E) phases.
On the contrary, TRF2 and POT1 remained more stably
associated with the telomeric DNA in RHPS4-treated
compared with untreated samples. Moreover, the typical
dip of two telomeric proteins during the G2 phase fol-
lowed by the rapid recovery of their binding was not
observed in RHPS4-treated cells. Western blotting
showed that none of the changes observed both in
RHPS4-untreated and treated cells were due to altered
Figure 2. RHPS4 blocks the cells in S–G2 phase of cell cycle. (A) Progression of cells through the cell cycle phases was analyzed by ﬂow cytometry
using BrdU. Untreated and RHPS4-treated HeLa cells after 3, 4 and 5 days of drug exposure were pulsed with BrdU for 15min, and after the
appropriate intervals in BrdU-free medium (from 4 to 16h) the DNA was denatured, incubated with anti-BrdU antibody and the BrdU-positive cells
were revealed with FITC-conjugated antibody. The percentage of BrdU-positive cells was reported inside the histogram. (B) The graphs represent the
percentage of BrdU-positive S phase cells evaluated at Day 3 (a), 4 (b) and 5 (c) of RHPS4 treatment. The mean of three independent experiments,
with SD is shown.
Nucleic Acids Research, 2009,Vol.37, No. 16 5357Figure 3. RHPS4 impairs telomere replication and alters the dynamics of telomeric proteins. BJ-HELT ﬁbroblasts were synchronized at the G1/S
boundary with HU, treated with RHPS4 or released in drug-free medium and harvested every 2h. Prior to harvest of each individual time point, the
cells were incubated with BrdU for 1h. (A) FACS analysis of untreated and RHPS4-treated BJ-HELT ﬁbroblasts released from G1/S block at the
indicated times. (B) ChIP experiments on synchronized BJ-HELT ﬁbroblasts incubated with BrdU. Precipitations were performed with antibodies
against TRF1 and TRF2. The precipitated DNA was analyzed by western blotting with anti-BrdU antibody. The total DNA (input) represents 10%
of genomic DNA (C) The graphs show the densitometric evaluation of three independent experiments, with error bars indicating the SD. (D) Protein
extracts from cells at the indicated times were subjected to ChIP experiments using antibodies against TRF1, TRF2 and POT1. IgG antibody was
used as negative control. The total DNA (input) represents 10 and 1% of genomic DNA. Southern blot analysis was performed by using telomeric or
ALU repeat-speciﬁc probes. (E) The signals obtained were quantiﬁed by densitometry, and the percentage of precipitated DNA was calculated as
a ratio of input signals and plotted. Four independent experiments were evaluated and error bars indicate the SD.
5358 Nucleic Acids Research, 2009, Vol. 37,No. 16levels of protein expression (Supplementary Figure 2).
Altogether, our results suggest that RHPS4, by stabilizing
G4 DNA at telomeres, can impair fork progression and/or
telomere processing.
Since WRN and BLM have been proposed to dissociate
unusual DNA structures that could block telomere repli-
cation and to solve aberrant replication intermediates, we
evaluated the eﬀect of RHPS4 on the expression of these
two proteins. The results reported in Figure 4A demon-
strate that WRN and even more the BLM helicases were
increased upon drug treatment. Moreover, both WRN
and BLM bound the telomeric sequences more eﬃciently
in RHPS4-treated compared with untreated samples
(Figure 4B and C). Functionally, the knock down of
BLM by RNA interference strategy (Figure 4D) markedly
increased RHPS4-induced damage (Figure 4E), showing
that BLM can be required to cop out the replication
defects caused by RHPS4.
We ﬁnally evaluated the consequence of telomere repli-
cation defects caused by RHPS4 by analyzing chromo-
some aberrations after 4 days of treatment, just before
induction of cell death. Fluorescence in situ hybridization
by using a telomeric PNA probe on metaphase spreads
showed that RHPS4 induced telomere instability as
revealed by a signiﬁcant increase of telomere aberration
with a mean of 4 0.9 damaged telomeres in RHPS4-
treated metaphases versus 1 0.1 in untreated controls.
Speciﬁcally, RHPS4 caused well-described telomere aber-
rations: telomere doublets at single chromatid ends and
both sister chromatid fusions and/or telomere fusions
between two distinct chromosomes (Figure 5). On the con-
trary, RHPS4 did not induce telomere losses or deletions
revealed as a decreased intensity or a lack of telomere
signal on one or both sister chromatids (Figure 5).
RHPS4 activates an ATR-dependent checkpoint pathway
We next analyzed the molecular pathway activated by
telomere replication defects caused by RHPS4 treatment.
Previously we showed that RHPS4-induced phosphoryla-
tion of H2AX at the telomeres involves the ATR kinase
(21, Supplementary Figure 3). This is in agreement with
several data indicating that ATR controls the downstream
response to replicational stress-inducing agents (27,
Supplementary Figure 4).
By using biochemical and microscopy techniques, we
further demonstrated here that, upon RHPS4 treatment
in BJ-HELT cells, ATR, its cofactor ATRIP and the DNA
damage response protein 53BP1 were activated and
co-localized with gH2AX (Figure 6A–C). Moreover, con-
focal microscopy experiments revealed that all the ATR
and 53BP1 foci are spatially close to TRF1 spots and the
signals in part overlap (Figure 6D and E), while to a lesser
extent partial co-localizations were observed between
ATRIP and TRF1 (see arrow heads). These results suggest
that not all the telomeres can have a stalled fork or telo-
meres/parts of telomeres have not replicated yet.
Although ATM is not required for the DNA damage
response triggered by RHPS4 (21, Supplementary
Figure 4. BLM and WRN helicases are increased and recruited to the telomeres upon RHPS4 treatment. (A) Western blot analysis of BLM and
WRN helicases in BJ-HELT cells untreated or treated with RHPS4 for 96h. (B) ChIP experiments on BJ-HELT ﬁbroblasts untreated and treated
with RHPS4. Protein extracts from cells during S and G2 phases of cell cycle were subjected to ChIP experiments using antibodies against BLM and
WRN. IgG antibody was used as negative control. The total DNA (input) represents 10 and 1% of genomic DNA. Southern blot analysis was
performed by using telomeric or ALU repeat-speciﬁc probes. (C) The signals obtained were quantiﬁed by densitometry, and the percentage of
precipitated DNA was calculated as a ratio of input signals and plotted. Three independent experiments were evaluated and error bars indicate the
SD. (D) Western blot analysis of BLM in siGFP and siBLM-transfected cells. (E) Western blot analysis of gH2AX in siGFP and siBLM transfected
cells untreated or treated with RHPS4.
Nucleic Acids Research, 2009,Vol.37, No. 16 5359Figure 3A–D), it is phosphorylated on Ser1981 following
the drug treatment and co-localized with damaged telo-
meres, as revealed by co-immunostaining against gH2AX
and TRF1 (Figure 7A and B). This activation is comple-
tely abrogated in ATR knock-down cells (Figure 7C–E),
placing ATR upstream of ATM and establishing a cross-
talk between the two kinases in response to RHPS4. Of
note, ATR-dependent ATM phosphorylation is a peculiar
characteristic of replicational stress-inducing agents,
while ATM works upstream to ATR during IR (27,
Supplementary Figure 5).
Analysis of transducer kinases in HeLa cells (containing
active ATM/ATR pathways; 28) revealed that Chk2 was
phosphorylated by RHPS4 and p53/p21 molecular death
targets were activated (Figure 7F). All these ﬁndings
strongly demonstrate that RHPS4 fully activates a DNA
damage response pathway leading to cell death.
We ﬁnally assessed the biological relevance of upstream
and downstream kinases by using cell lines with character-
ized deﬁciencies. The results demonstrated that RHPS4
induced a dose-dependent reduction of cell viability in
transformed ﬁbroblasts expressing inducible wild-type
ATR, but not in those expressing kinase inactive ATR
(which results in an ATR-dominant negative status).
Also HCT116, Chk2 and p21 defective cell lines were
resistant to RHPS4 treatment in terms of cell viability
(Figure 8). On the contrary, compared with the wild-
type cells, the p53 null cell viability was reduced to the
same extent (Figure 8). These results demonstrate that
while p53 does not inﬂuence the response of cells to
RHPS4 treatment, the lack of ATR, ChK2 and p21
makes cells resistant to the compound.
DISCUSSION
RHPS4 is a G4-interactive molecule possessing antitu-
moral activity because of its ability to rapidly induce tel-
omere damage and cell death independently of telomerase
inhibition (21). We reveal here that RHPS4 damages
telomeric chromatin during replication triggering an
ATR-dependent signaling pathway. Therefore, RHPS4
eﬃciently impairs the two main pathways of telomere
maintenance in dividing cells: elongation by telomerase
(29) and telomere replication (this study). This makes
this compound particularly suitable to target proliferating
cancer cells.
RHPS4 triggers damages in cells during S–G2 phase of
cell cycle by interfering with telomere replication. Indeed,
we found that RHPS4 speciﬁcally reduces the BrdU incor-
poration in the telomeric chromatin immunoprecipitated
with TRF1 and TRF2 antibodies without altering the
incorporation of BrdU into total DNA. In addition,
RHPS4 triggers a marked alteration of the typical
dynamic association of the telomeric proteins TRF1,
TRF2 and POT1 occurring during cell cycle (12).
Speciﬁcally, TRF1 dissociation, which occurs transiently
during S–G2 phase is signiﬁcantly increased by RHPS4
treatment, while, in the meantime, the amount of telo-
mere-bound TRF2–POT1 complex is increased. An expla-
nation of these results is that RHPS4 acts at a point after
TRF1 dissociation, i.e. during or just after fork passage,
preventing its re-association to the newly formed telomere.
Alternatively, RHPS4 might displace TRF1 prior to the
passage of the replisome, leading to fork stalling. In these
cases, the enhanced binding of TRF2 might simply be the
consequence of a lower abundance of TRF1. Another pos-
sibility is that the replication damage induced by RHPS4
leads to a speciﬁc recruitment of TRF2 and subsequently
to TRF1 release. Anyhow, the fact that the timing of
dissociation and re-association is diﬀerent between
TRF1 and TRF2–POT1 in response to RHPS4 and is in
agreement with previous work showing that the shelterin
components can be found in cells as separate subcom-
plexes (30,31). As revealed by RHPS4 treatment, these
subcomplexes might have speciﬁc roles during telomere
replication.
These results indicate that RHPS4 can impair or delay
the timing of telomere replication. As presented in
Supplementary Figure 6, one can imagine that RHPS4
interferes with telomere replication because it stabilizes
the various types of G4 structures that could be formed
at telomeres. In particular, RHPS4 could bind to
G4 formed during lagging-strand synthesis or at the
30-overhang or at the displaced strand of the D-loop,
which was proposed to form the basis of t-loop, or in
Figure 5. RHPS4 induces telomere aberrations. BJ-HELT ﬁbroblasts
were treated with 0.5mM RHPS4 for 96h and hybridized successively
with a telomeric PNA probe (in red) and then counterstained with
Hoechst (blue). Histograms show the mean of damaged telomeres per
cell in metaphase spreads.    t-test P-value <0.0001. Representative
images of the diﬀerent telomere aberrations are presented at the
bottom.
5360 Nucleic Acids Research, 2009, Vol. 37,No. 16G-loop during TERRA transcription or at TERRA itself.
This hypothesis is consistent with our results showing that
RHPS4 increases the expression and the telomeric associ-
ation of BLM and WRN that are principally involved in
unwinding G4 DNA as well as other secondary structures
that can block fork progression, such as D-loop. The func-
tional role of the BLM helicase has been directly assessed
by showing that a reduced expression of BLM markedly
Figure 6. RHPS4 activates ATR, its co-factors ATRIP and 53BP1. BJ-HELT ﬁbroblasts were synchronized, treated with 0.5mM RHPS4 or released in
drug-free medium for 6h and co-immunostained with anti-ATR, ATRIP, 53BP1 antibodies and anti-gH2AX or anti-TRF1. (A) Percentage of cells with
more than four co-localizations in control and RHPS4-treated samples. (B) Representative images of IF acquired with a Leica Deconvolution microscope
(magniﬁcation:  63). (C) Western blot analysis of ATR, ATRIP and 53BP1. (D) Percentage of cells with more than four co-localizations.
(E) Representative images of IF acquired by confocal microscope (magniﬁcation:  63). Control (white bars); RHPS4 (gray bars). The means of three
independent experiments with comparable results are shown.
Nucleic Acids Research, 2009,Vol.37, No. 16 5361increases drug-induced damage. Therefore, it appears that
an overexpression of the BLM helicase may provide a
means for RHPS4-treated cells to respond to telomere
replication defects. In agreement with this view, BLM is
often upregulated in cancer cells, probably to accommo-
date the alterations on replication due to oncogene
activation (32).
The G4 structures ‘locked’ by RHPS4 and located in
front of the replication fork could create topological
barriers (Supplementary Figure 6) leading to fork pausing
or stalling, an accumulation of superhelical stress and an
alteration of protein dynamics at telomeres. In agreement
with this scenario, RHPS4 shows a strong synergistic
interaction with camptothecin, a topoisomerase I inhibitor
(33), reduces BrdU incorporation at telomeres and alters
the binding of telomeric protein during S/G2 (this study).
Telomeric replication defects induced by RHPS4
treatment can result in a recruitment of homologous
Figure 7. RHPS4 triggers an ATR-dependent ATM damage signaling pathway. BJ-HELT ﬁbroblasts were treated with 0.5mM RHPS4 for 16h, ﬁxed
and co-immunostained with pospho-ATM on Ser1981 (p-ATM) and anti-gH2AX or TRF1 antibodies. Hoechst staining was used to mark nuclei. (A)
Representative images acquired by a deconvolution microscopy (magniﬁcation:  100) of p-ATM/gH2AX and p-ATM/TRF1. (B) Percentage of cells
with more than four p-ATM/gH2AX and p-ATM/TRF1 co-localizations. The mean of three independent experiments with comparable results is
shown. BJ-HELT ﬁbroblasts were transfected with 100mM of siGFP and siATR. After 48h, cells were treated with 0.5mM RHPS4 for 16h and
processed for IF against p-ATM. (C) Representative images of IF acquired with a Leica Deconvolution microscope (magniﬁcation:  40).
(D) Western blot analysis of ATR in siGFP and siATR transfected BJ-HELT cells. (E) Percentage of p-ATM-positive cells and western blotting
of p-ATM in the indicated samples. (F) Western blot analysis of the phosphorylated form of ChK1, ChK2 and p53 in HeLa cells untreated or treated
with RHPS4 for 4 days. The nonphosphorylated forms of the same proteins as well as the expression of p21 are also reported.
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mosome rearrangement. Indeed, cells treated with RHPS4
showed an increased frequency of chromosome aberra-
tions, previously described in other contexts in which
telomeres were destabilized: telomere doublets are charac-
terized by two telomere arrays (one in terminal position)
separated by various lengths of nontelomeric DNA, they
could result from an improper T-loop formation, which
could recombine in cis with internal sequences of DNA
giving rise to double stained telomeres (34), thus in agree-
ment with the hypothesis of RHPS4 interference with
terminal processing. Homologous recombination factors
are usually recruited at stalling forks. A pause or an
arrest of replication fork at telomeres could be resolved
by fusion between sister chromatids (8). Moreover, incor-
rectly capped telomeres are known to give rise to telomeric
fusions between diﬀerent chromosomes (35).
Of note, a short time exposure of tumor cells with low-
dose RHPS4 is suﬃcient to trigger replication defect but
not to stop cell proliferation, strongly supporting the
conclusion that the S–G2 phase-arrested cells observed
upon RHPS4 treatment are a consequence of telomere
replication defects, which represent the early event of
RHPS4-induced damages. However, long-term exposure
of RHPS4 creates chronic damages ultimately leading to
cell death.
Analysis of the molecular pathway activated by RHPS4
strongly supports the conclusion that this drug induces a
replication stress. Indeed, in our situation, similarly to
that triggered by relication stress-inducing agents, such
as HU and UV (27), ATR is the main kinase involved in
RHPS4 damage, while ATM functions downstream to
ATR leading to ChK2/p53/p21 activation. As a result,
blockade of ATR or genetic deﬁciency of ChK2 as well
as of p21 inhibits cell death, suggesting an important role
for ATR/ChK2/p21 molecules during RHPS4-induced tel-
omere damage. Interestingly, the status of p53 protein
does not inﬂuence the response of cells to RHPS4 treat-
ment. This is in agreement with our previous results show-
ing that RHPS4 is equally eﬀective in cells expressing both
wild-type and mutant p53 (20,21), including the BJ-HELT
ﬁbroblasts reported in this article in which p53 and Rb
pathways are functionally inactivated by SV40.
In conclusion, this work describes a new mechanism
through which G4 ligands can induce telomere damage,
raising the intriguing question of the role of G4 DNA in
the control of telomere replication. More interestingly, the
better characterization of the mode of action of RHPS4
might have implications for the selection of tumors that
are more likely responsive to the drug treatment leading to
the development of rational and more eﬀective drug
combinations.
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Supplementary Data are available at NAR Online.
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Figure 8. ATR-, ChK2- and p21-defective cells are resistant to RHPS4
treatment. The GM847 and GM847/ATR-KD cells expressing the wild-
type and inactive ATR kinase, the wild-type, ChK2- and p21-deﬁcient
HCT116 cells and the cells expressing the mutant p53 protein were
treated with RHPS4. The graphs represent the viability of RHPS4-
treated cells at 0.5 (open square) and 1mM (open triangle) drug con-
centration evaluated by MTT assay at the indicated time of treatment.
Data are expressed as percentage of cell viability compared with
untreated cells. The ﬁgures show representative experiments performed
in quintuplicate with SDs.
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